Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endogenous retrovirus group E member 5 (ERVE-5)
- Target
- ERVE-5
- Molecular classification
- Long non-coding RNA (lncRNA), Endogenous retrovirus (ERV) family
01
Overview
Endogenous retrovirus group E member 5 (ERVE-5, AC079466.1) is classified as a long non-coding RNA and belongs to the family of endogenous retroviral elements present in the human genome. Endogenous retroviruses are genetic sequences derived from ancient viral infections that have become fixed in species genomes over millions of years. While some lncRNAs are involved in the regulation of cellular processes and disease, ERVE-5 itself remains poorly characterized; there is minimal direct experimental or clinical evidence establishing its biological function or therapeutic relevance. Accordingly, ERVE-5 is not considered a canonical drug target, and its full biological significance is still under investigation.
- Other names
- AC079466.1ERVE-5
02
Mechanism of action
Not applicable, as there are no drugs reported to interact with this target.
03
Biological functions
As a lncRNA, its biological function is not fully annotated. Long non-coding RNAs typically regulate gene expression and are implicated in cellular processes such as chromatin remodeling, transcriptional regulation, and post-transcriptional modification.Some related lncRNAs have roles in extracellular matrix organization, receptor ligand activity, and possibly immune signaling.May participate in ceRNA (competing endogenous RNA) networks, regulating microRNAs and gene expression.
04
Disease associations
Some bioinformatics studies implicate related lncRNAs in cancer, particularly endometrial carcinoma and potentially in other tumor microenvironments.There is preliminary evidence for association with tumor progression and immune response modulation, but direct evidence for ERVE-5 itself remains inconclusive.There is no robust clinical evidence linking ERVE-5 directly to a specific disease, and it is not an "established biomarker or therapeutic target."
05
Safety considerations
None known, given lack of therapeutic intervention or targeting.
06
Interacting drugs
None known.
07
Biomarkers
No validated biomarkers for ERVE-5. It is not currently used for patient selection or efficacy monitoring.
Beyond the preview
Go deeper on Endogenous retrovirus group E member 5 (ERVE-5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endogenous retrovirus group E member 5 (ERVE-5).